lundi 6 octobre 2014

Evolucumab and PCSK9 need outcomes data

Why? Because LDL doesn't mean shit...



"No one is disputing that Zetia can lower levels of LDL "bad" cholesterol by 15 percent to 20 percent -- that had been shown in previous trials. However, whether that reduction led to any greater lowering of heart attack or stroke risk had remained unclear.



The new ENHANCE trial -- which involved patients with a genetic condition that causes abnormally high levels of blood cholesterol -- found no such added benefit. According to a statement released by the two drug companies Monday, researchers found no statistically significant difference in heart attacks or stroke among trial participants who took Zetia plus Zocor, a widely used cholesterol-lower drug, versus those who got Zocor alone."





Evolucumab and PCSK9 need outcomes data

Aucun commentaire:

Enregistrer un commentaire